A number of clinical pathologists from Cerba Laboratory recently presented some approaches on how to manage SARS CoV 2 variants during the clinical trial process.
Dr. Benedicte Roquebert is based in the microbiology department of Cerba Laboratory and works on emerging diseases, having authored 33 international publications on related topics.
Dr. Stephanie Haim-Boukobza has extensive experience working as a virologist in hospital and university settings, as well as private labs in France. She has been with Cerba since 2017 and became the Head of Infectology in 2018.
